These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 16394444)

  • 21. Imatinib mesylate: a new pill for chronic myelogenous leukemia.
    Parmar KK; King RS
    Cancer Pract; 2001; 9(5):263-5. PubMed ID: 11879324
    [No Abstract]   [Full Text] [Related]  

  • 22. Imatinib mesylate.
    Am J Health Syst Pharm; 2001 Dec; 58(23):2241-2. PubMed ID: 11765724
    [No Abstract]   [Full Text] [Related]  

  • 23. Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFRβ rearrangement and type 1 diabetes.
    Salaroli A; Loglisci G; Serrao A; Alimena G; Breccia M
    Ann Hematol; 2012 Nov; 91(11):1823-4. PubMed ID: 22623162
    [No Abstract]   [Full Text] [Related]  

  • 24. Photoinduced dermatitis and oral lichenoid reaction in a chronic myeloid leukemia patient treated with imatinib mesylate.
    Brazzelli V; Muzio F; Manna G; Moggio E; Vassallo C; Orlandi E; Fiandrino G; Lucioni M; Borroni G
    Photodermatol Photoimmunol Photomed; 2012 Feb; 28(1):2-5. PubMed ID: 22211996
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A patient of chronic myelogenous leukemia developing painful rash on feet.
    Kumar P; Das NK; Sil A; Chakrabarti P
    J Postgrad Med; 2012; 58(4):331-4. PubMed ID: 23298941
    [No Abstract]   [Full Text] [Related]  

  • 26. Unusual fluid retention with imatinib therapy for chronic myeloid leukemia.
    Ostro D; Lipton J
    Leuk Lymphoma; 2007 Jan; 48(1):195-6. PubMed ID: 17325868
    [No Abstract]   [Full Text] [Related]  

  • 27. Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders.
    Tsimberidou AM; Colburn DE; Welch MA; Cortes JE; Verstovsek S; O'Brien SM; Albitar M; Kantarjian HM; Giles FJ
    Cancer Chemother Pharmacol; 2003 Sep; 52(3):229-34. PubMed ID: 12783207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imatinib-induced nail hyperpigmentation in chronic myeloid leukemia.
    Prabhash K; Biswas G; Prasad N; Karant N; Sastry PS; Parikh PM
    Indian J Dermatol Venereol Leprol; 2006; 72(1):63-4. PubMed ID: 16481719
    [No Abstract]   [Full Text] [Related]  

  • 29. Gleevec: tailoring to fit.
    May TS
    Drug Discov Today; 2003 Mar; 8(5):188-9. PubMed ID: 12634004
    [No Abstract]   [Full Text] [Related]  

  • 30. Severe hemolytic anemia and skin reaction in a patient treated with imatinib.
    De Arriba JJ; Nerín C; García E; Gómez-Aldaraví L; Vila B
    Ann Oncol; 2003 Jun; 14(6):962. PubMed ID: 12796039
    [No Abstract]   [Full Text] [Related]  

  • 31. Long-term efficacy and safety of nilotinib therapy after imatinib failure in eosinophilic myeloproliferative neoplasm and ETV6-ABL rearrangement.
    Tiribelli M; Barraco D; Medeot M; Marin L; Ottaviani E; De Marchi F; Damiani D; Fanin R
    Ann Hematol; 2015 Aug; 94(8):1423-4. PubMed ID: 25900790
    [No Abstract]   [Full Text] [Related]  

  • 32. Myeloproliferative disorders.
    Murray J
    Clin Med (Lond); 2005; 5(4):328-32. PubMed ID: 16138485
    [No Abstract]   [Full Text] [Related]  

  • 33. Imatinib (STI-571)-induced exfoliative dermatitis in a Saudi patient with deck chair sign.
    Banka N; Aljurf M; Hamadah I
    Dermatology; 2003; 207(3):329-30. PubMed ID: 14571082
    [No Abstract]   [Full Text] [Related]  

  • 34. Philadelphia-negative secondary acute myeloid leukaemia during imatinib treatment for chronic phase chronic myeloid leukaemia.
    Ross DM; Jackson SR; Browett PJ
    Leuk Lymphoma; 2007 Jun; 48(6):1231-3. PubMed ID: 17577792
    [No Abstract]   [Full Text] [Related]  

  • 35. Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia.
    Kong JH; Yoo SH; Lee KE; Nam SH; Kwon JM; Lee SM; Chang HJ; Choi MY; Cho MS; Mun YC; Nam E; Lee SN; Seong CM
    Acta Haematol; 2007; 118(4):205-8. PubMed ID: 18030002
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leukemia. Q&A highlights.
    Frame D; Sessions J; Fausel C
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S22. PubMed ID: 18056929
    [No Abstract]   [Full Text] [Related]  

  • 37. The results of imatinib therapy for patients with primary eosinophilic disorders.
    Helbig G; Stella-Holowiecka B; Grosicki S; Bober G; Krawczyk M; Wojnar J; Reiter A; Hochhaus A; Holowiecki J
    Eur J Haematol; 2006 Jun; 76(6):535-6. PubMed ID: 16608506
    [No Abstract]   [Full Text] [Related]  

  • 38. Oral lichenoid eruption secondary to imatinib (Glivec).
    Ena P; Chiarolini F; Siddi GM; Cossu A
    J Dermatolog Treat; 2004 Jul; 15(4):253-5. PubMed ID: 15764042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pulmonary arterial hypertension and chronic myeloproliferative disorders.
    Di Stefano F
    Am J Respir Crit Care Med; 2006 Sep; 174(5):616. PubMed ID: 16931646
    [No Abstract]   [Full Text] [Related]  

  • 40. Imatinib-induced bone edema: case report and review of literature.
    dos Santos LV; Lima JP; Abdalla KC; Bragagnoli AC; Santos FA; dos Anjos Jácome A; Porto FE
    J Natl Compr Canc Netw; 2013 Oct; 11(10):1187-91. PubMed ID: 24142819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.